Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells

Leukemia

Volumn 26, Issue 6, 2012, Pages 1180-1188

  Congleton, J ^a   MacDonald, R ^a   Yen, A ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

AML differentiation; ATRA; dasatinib; Src inhibitors

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CASEIN KINASE II; DASATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; RAF PROTEIN; RETINOIC ACID;

ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; HUMAN; HUMAN CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CYCLE; CELL DIFFERENTIATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; HUMANS; IMMUNOPRECIPITATION; LEUKEMIA, MYELOID; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-RAF; PYRIMIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; THIAZOLES; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 84862000561     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.390     Document Type: Article

References (44)

1. Kim MP, Park SI, Kopetz S, Gallick GE. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res 2009; 335: 249-259.
2. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996; 56: 3589-3596. (Pubitemid 26251657)
3. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002; 21: 5766-5774. (Pubitemid 35315274)
4. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C. A critical role for Lyn in acute myeloid leukemia. Blood 2008; 111: 2269-2279. (Pubitemid 351451434)
5. Kropf PL, Wang L, Zang Y, Redner RL, Johnson DE. Dasatinib promotes ATRA-induced differentiation of AML cells. Leukemia 2010; 24: 663-665.
6. Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program 2006; 1: 178-184.
7. Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A et al. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. Leukemia 2007; 21: 403-410.
8. Robinson LJ, Xue J, Corey SJ. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Exp Hematol 2005; 33: 469-479. (Pubitemid 40387630)
9. Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 2008; 111: 3821-3829.
10. Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K et al. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res 2010; 16: 1149-1158.
11. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007; 29: 2289-2308.
12. Papageorgiou SG, Pappa V, Economopoulou C, Tsirigotis P, Konsioti F, Ionnidou ED et al. Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression. Leuk Res 2010; 34: e254-e256.
13. Stein B, Smith BD. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clin Ther 2010; 32: 804-820.
14. Klamova H, Faber E, Zackova D, Markova M, Voglova J, Cmunt E et al. Dasatinib in imatinib-resistant or-intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic. Neoplasma 2010; 57: 355-359.
15. Miranda MB, Redner RL, Johnson DE. Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiation. Mol Cancer Ther 2007; 6 (12 Part 1): 3081-3090.
16. Katagiri K, Yokoyama KK, Yamamoto T, Omura S, Irie S, Katagiri T. Lyn and Fgr protein-tyrosine kinases prevent apoptosis during retinoic acid-induced granulocytic differentiation of HL-60 cells. J Biol Chem 1996; 271: 11557-11562. (Pubitemid 26156001)
17. Notario V, Gutkind JS, Imaizumi M, Katamine S, Robbins KC. Expression of the fgr protooncogene product as a function of myelomonocytic cell maturation. J Cell Biol 1989; 109 (6 Part 1): 3129-3136. (Pubitemid 20011936)
18. Lee M, Kim JY, Anderson WB. Src tyrosine kinase inhibitor PP2 markedly enhances Ras-independent activation of Raf-1 protein kinase by phorbol myristate acetate and H2O2. J Biol Chem 2004; 279: 48692-48701. (Pubitemid 39625745)
19. Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008; 68: 9624-9633.
20. Shen M, Yen A. c-Cbl interacts with CD38 and promotes retinoic acid-induced differentiation and G0 arrest of human myeloblastic leukemia cells. Cancer Res 2008; 68: 8761-8769.
21. Yen A, Roberson MS, Varvayanis S, Lee AT. Retinoic acid induced mitogenactivated protein (MAP)/extracellular signal-regulated kinase (ERK) kinasedependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 1998; 58: 3163-3172. (Pubitemid 28335101)
22. Wang J, Yen A. A MAPK-positive feedback mechanism for BLR1 signaling propels retinoic acid-triggered differentiation and cell cycle arrest. J Biol Chem 2008; 283: 4375-4386.
23. Katagiri K, Katagiri T, Koyama Y, Morikawa M, Yamamoto T, Yoshida T. Expression of src family genes during monocytic differentiation of HL-60 cells. J Immunol 1991; 146: 701-707.
24. Congleton J, Jiang H, Malavasi F, Lin H, Yen A. ATRA-induced HL-60 myeloid leukemia cell differentiation depends on the CD38 cytosolic tail needed for membrane localization, but CD38 enzymatic activity is unnecessary. Exp Cell Res 2011; 317: 910-919.
25. Smith J, Bunaciu RP, Reiterer G, Coder D, George T, Asaly M et al. Retinoic acid induces nuclear accumulation of Raf1 during differentiation of HL-60 cells. Exp Cell Res 2009; 315: 2241-2248.
26. Yen A, Williams M, Platko JD, Der C, Hisaka M. Expression of activated RAF accelerates cell differentiation and RB protein down-regulation but not hypophosphorylation. Eur J Cell Biol 1994; 65: 103-113. (Pubitemid 24328182)
27. Zafrullah M, Yin X, Haimovitz-Friedman A, Fuks Z, Kolesnick R. Kinase suppressor of Ras transphosphorylates c-Raf-1. Biochem Biophys Res Commun 2009; 390: 434-440.
28. Ritt DA, Zhou M, Conrads TP, Veenstra TD, Copeland TD, Morrison DK. CK2 is a component of the KSR1 scaffold complex that contributes to Raf kinase activation. Curr Biol 2007; 17: 179-184. (Pubitemid 46107825)
29. Hagemann C, Kalmes A, Wixler V, Wixler L, Schuster T, Rapp UR. The regulatory subunit of protein kinase CK2 is a specific A-Raf activator. FEBS Lett 1997; 403: 200-202. (Pubitemid 27081494)
30. McKay MM, Ritt DA, Morrison DK. Signaling dynamics of the KSR1 scaffold complex. Proc Natl Acad Sci USA 2009; 106: 11022-11027.
31. Donella-Deana A, Cesaro L, Sarno S, Brunati AM, Ruzzene M, Pinna LA. Autocatalytic tyrosine-phosphorylation of protein kinase CK2 alpha and alpha' subunits: implication of Tyr182. Biochem J 2001; 357 (Part 2): 563-567. (Pubitemid 32701796)
32. Donella-Deana A, Cesaro L, Sarno S, Ruzzene M, Brunati AM, Marin O et al. Tyrosine phosphorylation of protein kinase CK2 by Src-related tyrosine kinases correlates with increased catalytic activity. Biochem J 2003; 372 (Part 3): 841-849. (Pubitemid 36760397)
33. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005; 6: 827-837. (Pubitemid 41568732)
34. Filbert EL, Nguyen A, Markiewicz MA, Fowlkes BJ, Huang YH, Shaw AS. Kinase suppressor of Ras 1 is required for full ERK activation in thymocytes but not for thymocyte selection. Eur J Immunol 2010; 40: 3226-3234.
35. Razidlo GL, Kortum RL, Haferbier JL, Lewis RE. Phosphorylation regulates KSR1 stability, ERK activation, and cell proliferation. J Biol Chem 2004; 279: 47808-47814. (Pubitemid 39540930)
36. Kortum RL, Lewis RE. The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells. Mol Cell Biol 2004; 24: 4407-4416. (Pubitemid 41071010)
37. Brummer T, Naegele H, Reth M, Misawa Y. Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene 2003; 22: 8823-8834. (Pubitemid 38021498)
38. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 2005; 17: 215-224. (Pubitemid 40138617)
39. Hong SK, Yoon S, Moelling C, Arthan D, Park JI. Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling. J Biol Chem 2009; 284: 33006-33018.
40. Morrison DK, Heidecker G, Rapp UR, Copeland TD. Identification of the major phosphorylation sites of the Raf-1 kinase. J Biol Chem 1993; 268: 17309-17316. (Pubitemid 23236968)
41. Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 1996; 84: 889-897. (Pubitemid 26106858)
42. St-Denis NA, Litchfield DW. Protein kinase CK2 in health and disease: From birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell Mol Life Sci 2009; 66: 1817-1829.
43. Santos SD, Verveer PJ, Bastiaens PI. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat Cell Biol 2007; 9: 324-330. (Pubitemid 46344612)
44. Brightman FA, Fell DA. Differential feedback regulation of the MAPK cascade underlies the quantitative differences in EGF and NGF signalling in PC12 cells. FEBS Lett 2000; 482: 169-174.